quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 16, 2026

Buy Nvidia Under $250 on Trump’s China Visit and Warsh’s Dovish AI Signals

View original at finance.yahoo.com
“after a $4.5 billion H20 charge in Q1 FY2026”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hyperscaler capex commitments from OpenAI, Anthropic, and Meta are locked in and insulated from rate policy changes

    60% confidence
  • Any thaw on H200 exports through the Trump-Xi track is pure upside to a number already guided north of $78 billion

    60% confidence
  • OpenAI committed to 10-plus gigawatts of Nvidia systems, Anthropic to 1 gigawatt, and Meta to millions of Blackwell and Rubin GPUs

    60% confidence
  • Reddit retail euphoria including a viral '1240% gain on NVDA' thread is a signal that tends to precede consolidation in the stock

    60% confidence
  • Nvidia's Q1 FY2027 revenue outlook of roughly $78.0 billion explicitly assumes zero Data Center compute revenue from China

    60% confidence
  • Kevin Warsh's reported willingness to keep Federal Reserve policy accommodative for AI capex protects hyperscaler spending on Nvidia systems

    60% confidence
  • NVDA at $235.74 screens attractively; analyst rates Buy under $250

    60% confidence
  • Computing demand is growing exponentially and the agentic AI inflection point has arrived

    60% confidence
  • Nvidia's Q1 FY2027 guidance excludes $12.5B in potential China H200/H20 revenue that could unlock if Trump-Xi trade talks produce an export carve-out

    60% confidence
  • The accelerating push by Tencent and Alibaba into homegrown AI chips creates competitive headwinds for the China upside thesis

    60% confidence

Data points we hold from this source

Federal Reserve · gdp3.75 percent_upper_bound
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Buy Nvidia Under $250 on Trump’s China Visit and Warsh’s Dovish AI Signals — Source | Via News | pt.VIA.NEWS